Cargando…

Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors

Thousands of leprosy patients not only suffer from physical deformities, but also either have or have had hepatitis B virus (HBV) coinfection. Polymorphisms of the complement system modulate susceptibility to leprosy, but genetic susceptibility to past or present HBV infection is unknown. We used se...

Descripción completa

Detalles Bibliográficos
Autores principales: Boldt, Angelica Beate Winter, Oliveira-Toré, Camila de Freitas, Kretzschmar, Gabriela Canalli, Weinschutz Mendes, Hellen, Stinghen, Sérvio Túlio, Andrade, Fabiana Antunes, Bumiller-Bini, Valéria, Gonçalves, Letícia Boslooper, Braga, Anna Carolina de Moraes, Stahlke, Ewalda von Rosen Seeling, Velavan, Thirumalaisamy P., Thiel, Steffen, de Messias-Reason, Iara José Taborda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904891/
https://www.ncbi.nlm.nih.gov/pubmed/33643280
http://dx.doi.org/10.3389/fimmu.2020.574457
_version_ 1783655012612702208
author Boldt, Angelica Beate Winter
Oliveira-Toré, Camila de Freitas
Kretzschmar, Gabriela Canalli
Weinschutz Mendes, Hellen
Stinghen, Sérvio Túlio
Andrade, Fabiana Antunes
Bumiller-Bini, Valéria
Gonçalves, Letícia Boslooper
Braga, Anna Carolina de Moraes
Stahlke, Ewalda von Rosen Seeling
Velavan, Thirumalaisamy P.
Thiel, Steffen
de Messias-Reason, Iara José Taborda
author_facet Boldt, Angelica Beate Winter
Oliveira-Toré, Camila de Freitas
Kretzschmar, Gabriela Canalli
Weinschutz Mendes, Hellen
Stinghen, Sérvio Túlio
Andrade, Fabiana Antunes
Bumiller-Bini, Valéria
Gonçalves, Letícia Boslooper
Braga, Anna Carolina de Moraes
Stahlke, Ewalda von Rosen Seeling
Velavan, Thirumalaisamy P.
Thiel, Steffen
de Messias-Reason, Iara José Taborda
author_sort Boldt, Angelica Beate Winter
collection PubMed
description Thousands of leprosy patients not only suffer from physical deformities, but also either have or have had hepatitis B virus (HBV) coinfection. Polymorphisms of the complement system modulate susceptibility to leprosy, but genetic susceptibility to past or present HBV infection is unknown. We used sequencing and multiplex sequence-specific PCR to genotype 72 polymorphisms of seven genes (MBL2, FCN1, FCN2, FCN3, MASP1, MASP2, C3) encoding components of the lectin pathway, and two genes encoding complement receptors (CR1, VSIG4) in 190 patients, of which 74 were positive for HBsAg and/or anti-HBc (HBV+, 93.2% with a resolved infection) and 116 lepromatous patients, and 408 HBV-blood donors. In addition, we tested for levels of proteins of the lectin pathway. We found no difference between serum concentrations of mannan-binding lectin (MBL), MBL-associated serine proteins (MASP-1, MASP-2, MASP-3, MAp44), ficolin-3 (FCN-3), soluble complement receptor 1 (sCR1) and MBL mediated C4 activation, measured by ELISA or TRIFMA in up to 167 HBV+ and HBV− patients. Haplotypes lowering protein levels or encoding dysfunctional proteins increased susceptibility to HBV infection: MBL2*LYQC (OR = 3.4, p = 0.02), MASP1*AC_CC (OR = 4.0, p = 0.015) and MASP2*1C2-l (OR = 5.4, p = 0.03). Conversely, FCN1*3C2 haplotype, associated with higher gene expression, was protective (OR = 0.56, P = 0.033). Other haplotypes associated with HBV susceptibility were: MASP2*2B1-i (OR = 19.25, P = 0.003), CR1*3A (OR = 2.65, P = 0.011) and VSIG4*TGGRCG (OR = 12.55, P = 0.014). Some polymorphisms in ficolin genes associated with lower protein levels increased susceptibility to leprosy/HBV infection: FCN*1 (OR = 1.66, P = 0.029), FCN2*GGGCAC (OR = 6.73, P = 0.008), and FCN3*del_del_C (OR = 12.54, P = 0.037), and to lepromatous disease/HBV infection: FCN2*TA (OR = 2.5, P = 0.009), whereas FCN2*MAG was associated with increased FCN-2 expression and resistance against coinfection (OR = 0.29, P = 0.026). These associations were independent of demographic factors and did not increase susceptibility to leprosy per se, except MASP2*1C2-l. Associations for FCN2, FCN3, MASP1, MASP2, and VSIG4 variants were also independent of each other. In conclusion, polymorphisms compromising activation of the lectin pathway of complement increase susceptibility to HBV infection, with ficolin polymorphisms playing a major role in modulating the susceptibility among leprosy patients.
format Online
Article
Text
id pubmed-7904891
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79048912021-02-26 Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors Boldt, Angelica Beate Winter Oliveira-Toré, Camila de Freitas Kretzschmar, Gabriela Canalli Weinschutz Mendes, Hellen Stinghen, Sérvio Túlio Andrade, Fabiana Antunes Bumiller-Bini, Valéria Gonçalves, Letícia Boslooper Braga, Anna Carolina de Moraes Stahlke, Ewalda von Rosen Seeling Velavan, Thirumalaisamy P. Thiel, Steffen de Messias-Reason, Iara José Taborda Front Immunol Immunology Thousands of leprosy patients not only suffer from physical deformities, but also either have or have had hepatitis B virus (HBV) coinfection. Polymorphisms of the complement system modulate susceptibility to leprosy, but genetic susceptibility to past or present HBV infection is unknown. We used sequencing and multiplex sequence-specific PCR to genotype 72 polymorphisms of seven genes (MBL2, FCN1, FCN2, FCN3, MASP1, MASP2, C3) encoding components of the lectin pathway, and two genes encoding complement receptors (CR1, VSIG4) in 190 patients, of which 74 were positive for HBsAg and/or anti-HBc (HBV+, 93.2% with a resolved infection) and 116 lepromatous patients, and 408 HBV-blood donors. In addition, we tested for levels of proteins of the lectin pathway. We found no difference between serum concentrations of mannan-binding lectin (MBL), MBL-associated serine proteins (MASP-1, MASP-2, MASP-3, MAp44), ficolin-3 (FCN-3), soluble complement receptor 1 (sCR1) and MBL mediated C4 activation, measured by ELISA or TRIFMA in up to 167 HBV+ and HBV− patients. Haplotypes lowering protein levels or encoding dysfunctional proteins increased susceptibility to HBV infection: MBL2*LYQC (OR = 3.4, p = 0.02), MASP1*AC_CC (OR = 4.0, p = 0.015) and MASP2*1C2-l (OR = 5.4, p = 0.03). Conversely, FCN1*3C2 haplotype, associated with higher gene expression, was protective (OR = 0.56, P = 0.033). Other haplotypes associated with HBV susceptibility were: MASP2*2B1-i (OR = 19.25, P = 0.003), CR1*3A (OR = 2.65, P = 0.011) and VSIG4*TGGRCG (OR = 12.55, P = 0.014). Some polymorphisms in ficolin genes associated with lower protein levels increased susceptibility to leprosy/HBV infection: FCN*1 (OR = 1.66, P = 0.029), FCN2*GGGCAC (OR = 6.73, P = 0.008), and FCN3*del_del_C (OR = 12.54, P = 0.037), and to lepromatous disease/HBV infection: FCN2*TA (OR = 2.5, P = 0.009), whereas FCN2*MAG was associated with increased FCN-2 expression and resistance against coinfection (OR = 0.29, P = 0.026). These associations were independent of demographic factors and did not increase susceptibility to leprosy per se, except MASP2*1C2-l. Associations for FCN2, FCN3, MASP1, MASP2, and VSIG4 variants were also independent of each other. In conclusion, polymorphisms compromising activation of the lectin pathway of complement increase susceptibility to HBV infection, with ficolin polymorphisms playing a major role in modulating the susceptibility among leprosy patients. Frontiers Media S.A. 2021-02-11 /pmc/articles/PMC7904891/ /pubmed/33643280 http://dx.doi.org/10.3389/fimmu.2020.574457 Text en Copyright © 2021 Boldt, Oliveira-Toré, Kretzschmar, Weinschutz Mendes, Stinghen, Andrade, Bumiller-Bini, Gonçalves, Braga, Stahlke, Velavan, Thiel and de Messias-Reason http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Boldt, Angelica Beate Winter
Oliveira-Toré, Camila de Freitas
Kretzschmar, Gabriela Canalli
Weinschutz Mendes, Hellen
Stinghen, Sérvio Túlio
Andrade, Fabiana Antunes
Bumiller-Bini, Valéria
Gonçalves, Letícia Boslooper
Braga, Anna Carolina de Moraes
Stahlke, Ewalda von Rosen Seeling
Velavan, Thirumalaisamy P.
Thiel, Steffen
de Messias-Reason, Iara José Taborda
Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors
title Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors
title_full Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors
title_fullStr Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors
title_full_unstemmed Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors
title_short Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors
title_sort hepatitis b virus infection among leprosy patients: a case for polymorphisms compromising activation of the lectin pathway and complement receptors
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904891/
https://www.ncbi.nlm.nih.gov/pubmed/33643280
http://dx.doi.org/10.3389/fimmu.2020.574457
work_keys_str_mv AT boldtangelicabeatewinter hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors
AT oliveiratorecamiladefreitas hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors
AT kretzschmargabrielacanalli hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors
AT weinschutzmendeshellen hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors
AT stinghenserviotulio hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors
AT andradefabianaantunes hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors
AT bumillerbinivaleria hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors
AT goncalvesleticiaboslooper hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors
AT bragaannacarolinademoraes hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors
AT stahlkeewaldavonrosenseeling hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors
AT velavanthirumalaisamyp hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors
AT thielsteffen hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors
AT demessiasreasoniarajosetaborda hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors